Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Clinical Outcomes
100%
Mantle Cell Lymphoma
100%
Clinical Behavior
100%
Immunophenotypic Features
100%
Progression-free Survival
27%
Overall Survival
27%
Prognostic Score
27%
Initial Treatment
18%
Clinical Presentation
18%
CD23
18%
White Blood Cell Count
18%
Lymphocytosis
18%
Mantle Cell Lymphoma International Prognostic Index
18%
No Significant Difference
9%
Clinical Response
9%
Co-expression
9%
Newly Diagnosed
9%
Aberrations
9%
Response to Therapy
9%
Patient Selection
9%
Response to Treatment
9%
Cyclin D1 (CCND1)
9%
Laboratory Parameters
9%
Aberrancy
9%
CD5+
9%
Immunochemotherapy
9%
CD10
9%
Immunophenotyping
9%
Statistically Significant Difference
9%
Prognostic Difference
9%
Neuroscience
Leukocyte
100%
Behavior (Neuroscience)
100%
CD23
100%
CD5
50%
Cyclin D1
50%
Immunophenotyping
50%
Medicine and Dentistry
Mantle Cell Lymphoma
100%
Progression Free Survival
27%
Overall Survival
27%
Leukocyte
18%
Cell Count
18%
Lymphocytosis
18%
Mantle Cell Lymphoma International Prognostic Index
18%
Cyclin D1
9%
Immunophenotyping
9%
Independent Factor
9%
Nursing and Health Professions
Mantle Cell Lymphoma
100%
Overall Survival
27%
Progression Free Survival
27%
Leukocyte Count
18%
Lymphocytosis
18%
Mantle Cell Lymphoma International Prognostic Index
18%
Immunophenotyping
9%
Cyclin D1
9%
Pharmacology, Toxicology and Pharmaceutical Science
Mantle Cell Lymphoma
100%
Progression Free Survival
23%
Overall Survival
23%
Lymphocytosis
15%
Cyclin D1
7%